Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Aaron W. Michels"'
Autor:
Taylor K. Armstrong, Kimber M. Simmons, Angela M. Mitchell, Aimon A. Alkanani, Erin E. Baschal, Kristen A. McDaniel, Liping Yu, Aaron W. Michels, Laura Pyle
Publikováno v:
Diabetes. 69:1763-1769
Certain HLA class II genes increase the risk for type 1 diabetes (T1D) development while others provide protection from disease development. HLA class II alleles encode MHC proteins on antigen-presenting cells, which function to present peptides and
Autor:
Aimon A. Alkanani, Laurie G. Landry, Clayton E. Mathews, Laura Pyle, Amanda M. Anderson, Alvin C. Powers, Mark A. Atkinson, Maki Nakayama, Aaron W. Michels, Bart O. Roep
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance Insulin is a major self-antigen in type 1 diabetes (T1D), and as such, insulin-based immunotherapies have been trialed to treat the underlying autoimmunity but with minimal clinical benefit. Here, we comprehensively assessed reactivity t
Autor:
Erin E. Baschal, Kathleen Waugh, Maki Nakayama, Aaron W. Michels, Aimon K. Alkanani, Marian Rewers, Angela M. Mitchell, Laurie G. Landry, Taylor K. Armstrong, Kristen McDaniel
Publikováno v:
Diabetes. 70
Type 1 diabetes (T1D) results from the T cell-mediated destruction of insulin-producing pancreatic β-cells as evidenced by CD8 and CD4 T cells being present within the inflamed islets of recent-onset T1D organ donors. We isolated, sequenced the T ce
Publikováno v:
Current Opinion in Endocrinology, Diabetes & Obesity. 26:90-95
PURPOSE OF REVIEW: To review the recent findings that small ‘drug-like’ compounds block disease-specific HLA molecules in type 1 diabetes (T1D). RECENT FINDINGS: The predominant genetic risk for developing T1D, the immune mediated form of diabete
Autor:
Laurie G. Landry, Amanda M. Anderson, Holger A. Russ, Liping Yu, Sally C. Kent, Mark A. Atkinson, Clayton E. Mathews, Aaron W. Michels, Maki Nakayama
Publikováno v:
Frontiers in Endocrinology
Frontiers in Endocrinology, Vol 12 (2021)
Frontiers in Endocrinology, Vol 12 (2021)
Proinsulin is an abundant protein that is selectively expressed by pancreatic beta cells and has been a focus for development of antigen-specific immunotherapies for type 1 diabetes (T1D). In this study, we sought to comprehensively evaluate reactivi
Autor:
Kimber M, Simmons, Angela M, Mitchell, Aimon A, Alkanani, Kristen A, McDaniel, Erin E, Baschal, Taylor, Armstrong, Laura, Pyle, Liping, Yu, Aaron W, Michels
Publikováno v:
Diabetes
Certain HLA class II genes increase the risk for type 1 diabetes (T1D) development while others provide protection from disease development. HLA class II alleles encode MHC proteins on antigen-presenting cells, which function to present peptides and
Autor:
Stephanie Case, Katherine J. Seidl, Kristen McDaniel, Samuel L. Ellis, Viral N. Shah, Peter A. Gottlieb, Erin E. Baschal, David A. Ostrov, Laura Pyle, Aaron W. Michels, Satish K. Garg, Mark A. Atkinson, Aimon K. Alkanani, Bernadette Pöllinger
Publikováno v:
Journal of Clinical Investigation. 128:1888-1902
Major histocompatibility (MHC) class II molecules are strongly associated with many autoimmune disorders. In type 1 diabetes (T1D), the DQ8 molecule is common, confers significant disease risk, and is involved in disease pathogenesis. We hypothesized
Publikováno v:
Diabetes. 68
Autoimmune disorders such rheumatoid arthritis (RA) harbor autoantibodies against a variety of post-translationally modified (PTM) proteins. We aimed to investigate whether PTM epitopes of IA-2, a major autoantigen related to type 1 diabetes (T1D), a
Publikováno v:
Diabetes. 68
Hybrid insulin peptides (HIPs) are unique post-translationally modified antigens whereby derivatives of proinsulin (PI) form peptide bonds with endogenous granule peptides. HIPs have been identified in mouse β-cell extracts and human islets by mass
Autor:
Marian Rewers, Yong Gu, Liping Yu, Aaron W. Michels, Jeremy Cheng, Kathleen Waugh, Xiaofan Jia, Zhiyuan Zhao, Tao Yang, Dongmei Miao
Publikováno v:
EBioMedicine
Islet autoantibodies (IAbs) are the most reliable biomarkers to assess the risk of progression to clinical type 1 diabetes (T1D) and there are four major biochemically identified IAbs currently used in clinical trials that are equally important for d